New cocktail targets Hard-to-Treat stomach cancer
NCT ID NCT05632939
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal junction cancer that cannot be surgically removed. The main goals are to check safety, find the best dose, and see if the combination shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASKB589 (a monoclonal antibody targeting CLDN18.2) combined with chemotherapy (oxaliplatin and capecitabine) and an immunotherapy (sintilimab or tislelizumab)
What this could lead to
If it works, this combination could offer a new first-line treatment option for people with advanced gastric cancer that cannot be removed by surgery.
What could go wrong
This is an early-phase trial with only 62 participants, so the main goal is safety and dosing—not yet proving the treatment works. Side effects from the drug combination could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100089, China